VEGFR2 Kinase Inhibitor III CAS: 204005-46-9
MF: C15H14N2O
MW: 238.28
A VEGFR2, Met, RET, PDGFR, and ALK inhibitor.

VEGFR2 Kinase Inhibitor III (CAS 204005-46-9)

VEGFR2 Kinase Inhibitor III | CAS 204005-46-9 is rated 5.0 out of 5 by 1.
  • y_2020, m_5, d_24, h_14
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.8
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202851, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 144ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: Semaxanib; SU 5416
Application: VEGFR2 Kinase Inhibitor III is a VEGFR2, Met, RET, PDGFR, and ALK inhibitor
CAS Number: 204005-46-9
Purity: ≥97%
Molecular Weight: 238.28
Molecular Formula: C15H14N2O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

VEGFR2 Kinase Inhibitor III is a cell-permeable ATP-competitive inhibitor of Flk-1 (VEGFR2/KDR, kinase insert domain receptor), which is the major growth factor for vascular endothelial cells. This receptor is a type III tyrosine kinase receptor that functions as the main mediator of VEGF-induced endothelial proliferation, survival, and migration. Studies suggest that VEGFR2 Kinase Inhibitor III also inhibits a variety of other receptors such as Met, Flt-3/Flk-2 (FLT-3 receptor tyrosine kinases), Ret, c-Kit, PDGFR, c-Abl and Arg (ABL), and ALK. In addition, VEGFR2 kinase inhibitor III regulates the signaling pathways used by oncogenic RET-transfected cells by regulating the extracellular signal regulated kinase (ERK) and JNK pathways.


References

1. Vajkoczy, P., et al. 1999. Neoplasia. 1: 31-41. PMID: 10935468
2. Mologni, L., et al. 2006. J. Mol. Endocrinol. 37: 199-212. PMID: 17032739
3. Komi, Y., et al. 2009. Cancer Sci. 100: 269-277. PMID: 19200258

Physical State :
Solid
Solubility :
Soluble in DMSO (5 mg/ml), and ethanol (100 mM). Insoluble in water.
Storage :
Store at 4° C
Melting Point :
221-222° C
Boiling Point :
481.41° C at 760 mmHg (Predicted)
Density :
1.26 g/cm3 (Predicted)
Refractive Index :
n20D 1.68 (Predicted)
IC50 :
proliferation of HUVEC50s induced by VEGF: IC50 = 50 nM; autophosphorylation of internal tandem duplication: IC50 = 0.1 µM; autophosphorylation of wild type Fms-like tyrosine kinase 3: IC50 = 0.1 µM; VEGF-R: IC50 = 1.04 µM (NIH 3T3 cells overexpressing Flk-1); Oxytocin-R: EC5050 = 11.47 µM (human); AVP Receptor V1a: EC5050 = 12.07 µM (human); PDGF-R tyrosine kinases: IC50 = 20 µM (NIH 3T3 cells overexpressing Flk-1); proliferation of HUVEC50s induced by EC50GS: IC50 = 30.5 µM; proliferation of HUVEC50s induced by bFGF: IC50 = 5.3 µM
pK Values :
pKa: 13.18 (Predicted), pKb: 1.53 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
5329098
MDL Number :
MFCD01940922
SMILES :
CC1=CC(=C(N1)/C=C\\2/C3=CC=CC=C3NC2=O)C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

VEGFR2 Kinase Inhibitor III (CAS 204005-46-9) Product Citations

See how others have used VEGFR2 Kinase Inhibitor III (CAS 204005-46-9). Click on the entry to view the PubMed entry .

Citations 1 to 4 of 4 total

PMID: # 26699078  Giordano, A. et al. 2016. Vascul. Pharmacol. 80: 67-74.

PMID: # 25450973  Lahiani, A. et al. 2015. Biochim. Biophys. Acta. 1853: 422-30.

PMID: # 25886469  Cui, HJ. et al. 2015. BMC Complement Altern Med. 15: 91.

PMID: # 24751361  Giordano, A. et al. Vascul. Pharmacol. 61: 63-71.

Citations 1 to 4 of 4 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 118ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Lahiani Lahiani, et al. (PubMed ID 25450973) found that pre-treating mesenchymal stem cells with 240ng/ml of Semaxanib (VEGFR2 Kinase Inhibitor III) reduced the growth factors and co-culture conditioned medium effects by 70% and 20% respectively. -SCBT Publication Review
Date published: 2015-03-06
  • y_2020, m_5, d_24, h_14
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.8
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202851, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 21ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.